The Lytic Effects of Detergent Sclerosants on Erythrocytes, Platelets, Endothelial Cells and Microparticles are Attenuated by Albumin and other Plasma Components in Vitro  by Parsi, K. et al.
Eur J Vasc Endovasc Surg (2008) 36, 216e223The Lytic Effects of Detergent Sclerosants on
Erythrocytes, Platelets, Endothelial Cells and
Microparticles are Attenuated by Albumin
and other Plasma Components in VitroK. Parsi a,b,*, T. Exner a, D.E. Connor a,b, A. Herbert a,b,
D.D.F. Ma a,b, J.E. Joseph a,ba Haematology Research Laboratory, St Vincent’s Hospital, Sydney, Australia
b The University of New South Wales, Sydney, Australia
Submitted 18 December 2007; accepted 3 March 2008
Available online 8 April 2008KEYWORDS
Sclerosants;
Haemolysis;
Platelets;
Endothelial cells;
Microparticles;
Albumin* Corresponding author. Dr. K. Parsi,
tralia. Tel.: þ612 92958422; fax: þ61
E-mail address: kparsi@ozemail.co
1078-5884/$34 ª 2008 European Socie
doi:10.1016/j.ejvs.2008.03.001Abstract Objective: To investigate the lytic effects of sodium tetradecyl sulphate (STS) and
polidocanol (POL) on erythrocytes, platelets, endothelial cells and platelet-derived micropar-
ticle (PDMP) formation in vitro and the potential protective effects of serum albumin and
agents such as procaine.
Materials and methods: The effects of sclerosants were studied in blood samples obtained
from normal individuals. Absorbance densitometry was used to assess the lytic effects of scler-
osants on blood cells and cultured human microvascular endothelial cells (HMEC) in plasma and
in saline. PDMP were quantified by flow cytometry.
Results: Haemolysis occurred in whole blood at sclerosant concentrations greater than 0.25%
for STS and above 0.45% for POL. Similar concentrations of both agents caused platelet and
endothelial cell lysis. Both sclerosants released PDMP at low concentrations but destroyed
PDMP at higher concentrations. Albumin significantly reduced the lytic effect of both sclero-
sants on all cells but had a greater inhibitory effect on POL. Protamine at 0.01% had a neutra-
lising effect on STS, whereas procaine and lignocaine showed no such activity.
Conclusions: Sclerosants at therapeutic concentrations lyse blood cells and endothelial cells
in vitro. This effect is strongly reduced by serum albumin possibly contributing towards the
low incidence of thromboembolic complications of sclerotherapy.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Department of Haematology, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, NSW 2010, Aus-
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Detergent sclerosants such as sodium tetradecyl sulphate
(STS) and polidocanol (POL) are widely known to have lytic
effects on endothelial cells.1 The destruction of the endo-
thelial lining of the vessel wall leads to exposure of the
sub-endothelial collagen and a cascade of events that can
either lead to endovascular sclerofibrosis, sclerothrombosis
or even thrombophlebitis.1
Despite the acknowledged lytic effects that these drugs
have on endothelial cells, little is known about their effects
on circulating blood cells and platelets. The related
literature remains contradictory with some authors report-
ing these sclerosants to be non-haemolytic in vitro2 while
others have reported them to cause haematuria3 or haemo-
globinuria2,4 when used clinically in high volumes. In this
study, we investigated the haemolytic effects of these
agents in vitro.
We have previously reported on the effects of detergent
sclerosants on clotting times, clotting factors, platelets and
formation of platelet-derived microparticles (PDMP).5 At
low concentrations, both drugs shorten phospholipid sensi-
tive clotting times and demonstrate procoagulant proper-
ties in vitro. This is achieved by damage to platelet
membranes and the release of procoagulant PDMP. At
high concentrations, STS destroys platelets and PDMP,
prolongs the clotting times and demonstrates anticoagulant
properties in vitro. By contrast, high concentration POL
does not prolong the clotting times to the same extent.5
Clinically, the sclerosing effects of these drugs are
thought to be limited to a short distance and usually
more than a single injection is required to sclerose a vein
segment which is more than a few centimetres long. The
lack of distal sclerosing power has been presumed to be due
to dilution of these agents in blood.1,6 Similarly, the low
thrombotic complication rate of sclerotherapy and the
rarity of distal complications has been presumed to be
due to dilution effects. Here, we investigated the possibil-
ity of a neutralising interaction between detergent sclero-
sants and albumin and human plasma.
Another rare but important complication of sclerother-
apy is tissue necrosis and skin ulceration.1,7 The local
anaesthetic Procaine has been thought to bind and neutral-
ise STS and is used clinically if impending STS induced tissue
necrosis is suspected.8 We also investigated the presumed
protective benefit of Procaine and similar agents such as
lignocaine hydrochloride and protamine sulphate in an
in vitro setting.
Materials and Methods
Sample collection
Blood from normal healthy volunteer donors was obtained by
clean venepuncture and collected in Vacutainer tubes
(Becton Dickinson, USA) containing 0.109 M trisodium citrate.
Sclerosants and other agents
STS was obtained as FIBRO-VEIN 3% (Australian Medical and
Scientific Limited, Chatswood, NSW, Australia) and POL asAETHOXYSKLEROL 3% (Chemische Fabrik Kreussler & Co,
GMBH, Wiesbaden, Germany). Bovine serum albumin (BSA)
was obtained from Bovogen (Melbourne, Vic, Australia).
20 g of BSA was dissolved in 100 ml of saline to produce
a stock solution. A 4% physiologic concentration of albumin
was used in these experiments. Procaine hydrochloride 2%
was obtained as PROCAINE HYDROCHLORIDE INJECTION
(DBL) from Mayne Pharma International (Melbourne, Vic,
Australia). Lignocaine hydrochloride 2% was obtained as
XYLOCAINE AMPOULES (PLAIN) INJECTION from AstraZeneca
Pty Ltd (North Ryde, NSW, Australia). Protamine sulphate
1% was obtained as PROTAMINE SULPHATE INJECTION BP
from Aventis Pharma Pty Limited Sanofi-Aventis Group
(Macquarie Park, NSW, Australia).
Sample preparation
Preparation of Platelet Rich and Platelet Poor Plasma.
Platelet rich plasma (PRP) was prepared by centrifugation
of whole blood samples at 150 g for 10 minutes. Platelet
poor plasma (PPP) was obtained by centrifugation of
citrated blood at 1500 g for 20 minutes. Platelet counts
were carried out with a Cell-Dyn 4000 (Abbott Diagnostics
Division, Santa Clara, CA, USA).
Preparation of Washed Red Cells. Washed red cells were
obtained by centrifugation of citrated whole blood. PPP
was removed and the remaining red cells were mixed
with a large volume of saline followed by recentrifugation
at 2000 g for 15 minutes. The supernatant was then
discarded and the washed red cells were resuspended in
a volume of saline equal to the packed cell volume of 50%.
Preparation of Washed Platelets. PRP was centrifuged
for 15 minutes at 3000 g to sediment platelets which were
then pooled and washed in 20 ml total volume of 0.15 M
NaCl, 0.01 M HEPES, 0.001 M EDTA pH 7.4 solution (diluting
buffer). After centrifuging down again at 3000 g for 15 min-
utes and discarding the supernatant, the washed platelets
were resuspended in 4.5 ml of HEPES-buffered saline. This
was described as ‘‘10’’ washed platelet suspension
because it would have contained most of the original plate-
lets in 1/10th the volume of the blood (45 ml).
Haemolysis studies
A) Detection of Haemoglobin Released From Lysed Red
Blood Cells. The haemolytic effect of sclerosants was
assessed by the addition of plasma containing various
concentrations of sclerosants to 1/10th its volume of sedi-
mented red blood cells that had been centrifuged down
in microwells. Red blood cells were sedimented in micro-
wells by centrifugation. The supernatant was removed
and the pellet resuspended in plasma containing various
concentrations of sclerosants. The sclerosants were
dispersed into the plasma component before resuspending
the red cells to avoid excessive localised lytic effects of
high concentration sclerosants. After a ten minute incuba-
tion, the microplate was again centrifuged. The superna-
tant was liberated and transferred to another microplate.
Free haemoglobin was then measured using a microplate
reader (Titertek Multiskan MCC, Finland) at an absorbance
of 520 nm.9 Absorbances were converted to percent
Figure 1 Haemolysis induced by sclerosants added to normal
plasma containing 50% packed red cells. STS (C), POL (:).
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constructed from dilutions of red cells that had been fully
haemolysed with excess STS.
B) Detection of Protective Effects of Albumin on
Haemolysis. To examine the potentially protective effects
of albumin, mixtures of sclerosants and bovine serum albu-
min (BSA) in saline were first prepared in round bottomed
microwells. Next, small volumes of washed red cells were
added and the mixtures were centrifuged at 200 g for 10
minutes. Unlysed red cells sedimented to form a compact
spot in the centre of the wells. Absorbance measurements
were then carried out at 405 nm.
Platelet lysis studies
Platelet lysis was assessed by means of changes in
turbidity as previously described.5 The inhibition of plate-
let lysis by the addition of bovine serum albumin (BSA) was
assessed in mixtures of washed platelet suspensions and
sclerosants. BSA was diluted to a concentration of 16%
using diluting buffer. Serial dilutions were carried out
down 2 columns of flat bottomed wells in a microplate
with the bottom well containing 0% BSA. To each well,
small volumes of the 10 washed platelet suspension
were dispensed and absorbances were measured at
414 nm in a microplate reader (Titertek Multiskan MCC,
Finland). The instrument was blanked with a column of
buffer-containing wells before each reading. Small
volumes of STS and POL were then added to the respective
columns for a final sclerosant concentration of 0.015%.
Absorbances were measured and then additional volumes
of sclerosants were added stepwise to achieve a final
concentration of 0.6%.
Effect of plasma on the release of
platelet-derived microparticles
To examine the protective effects of plasma components,
PDMP formation in response to STS or POL was assessed in
both washed platelet samples and PRP. Samples (0.08 ml)
were incubated with saline (0.02 ml) containing varying
concentrations of sclerosant for 30 minutes. 0.05 ml of
this mixture was then diluted using 0.2 ml of 0.02 M HEPES
pH 7.0 buffered 0.15 M sodium chloride solution. 0.01 ml
of this mixture was then added to CD41a-PerCP-Cy5.5
antibody (0.005 ml) and Annexin V-APC (0.002 ml) with
the volume made up to 0.05 ml using HEPES-bufferred
saline solution containing 2.5 mM CaCl2. This was incu-
bated for 30 minutes before the addition of 1 ml HEPES
buffer containing 2.5 mM CaCl2. Counting was performed
using TRU-Count tubes. Platelet-derived microparticles
(PDMP) were defined as events, less than 1.09 mm in
diameter that bound Annexin V and CD41a-PerCP-Cy5.5.
Neutralisation of haemolytic effects of
sclerosants by procaine, lignocaine
and protamine
We investigated the potential protective benefits of these
drugs in comparison with albumin. Microwells were filled
with increasing concentrations of sclerosants in salineand then 1% washed red cells were added. After mixing
and centrifuging, absorbances at 405 nm were determined
in a microplate reader. These experiments were done
with washed red cells in saline to avoid interference from
plasma proteins.
Endothelial cell lysis
A human microvascular endothelial cell line (HMEC-1)10 was
cultured to confluence in endothelial growth medium:
MCDB131 (JRH Biosciences, Lenexa, KS, USA) containing
10% Fetal Bovine Serum, Penicillin-Streptomycin and L-
Glutamine (Gibco Invitrogen, Carlsbad, CA, USA) in 96
well microplates pre-coated with human fibronectin (Gibco
Invitrogen). Mixtures of sclerosants and BSA or plasma
dilutions were prepared in a separate microplate and added
to the microwells after a single wash with saline. Following
a 10 minute incubation at 20 C, the solutions were gently
removed, the residual cells washed twice with saline, dried
and stained with Leishman’s stain. Residual adherent
material representing non-lysed cells was quantified by
densitometry at 540 nm.
Results
Haemolysis studies
STS concentrations above 0.25% caused haemolysis in
plasma whereas POL concentrations above 0.45% were
necessary to induce haemolysis in this system (Fig. 1).
Fig. 2 shows the progressive inhibitory effects of albu-
min on the haemolytic activity of the sclerosants in saline.
In the absence of albumin, much lower concentrations
of both agents induced haemolysis. STS induced haemoly-
sis at 0.02% and POL at 0.005%. Increasing concentrations
Figure 2 Haemolysis inducedby sclerosants in thepresence of
varying concentrations of bovine serum albumin (BSA 8%>, 4%
,, 2%6, 1% , 0.5%, 0.25% *, 0.125%, 0%þ). (a) STS, (b) POL.
Table 1 Effects of sclerosants on red blood cells and
platelets in saline, with 4% BSA present, and in whole blood
STS (%) POL (%)
Red cells
In saline alone 0.006 (1) 0.0035 (1)
In salineþ 4% BSA 0.2 (33.3) 0.1 (28.6)
In whole blood 0.3 (50) 0.57 (163)
Platelets
In saline alone 0.03 (1) 0.03 (1)
In salineþ 4% BSA 0.3 (10) 0.3 (10)
In whole blood See below* 0.3 (10)
Results extracted from 50% lysis points in Figs. 2a & b and 3a &
b and Ref. 5. A 4% BSA concentration was chosen as the physio-
logic concentration.
* Due to a precipitate of apolipoprotein B and fibrinogen the
turbidity rises after an initial drop with STS in whole blood
and hence measurement of 50% platelet lysis with this method
cannot be achieved.
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sclerosants to induce haemolysis. STS was 50 fold and
POL was 163 fold less haemolytic in blood than in saline
(Table 1).Platelet lysis studies
In the absence of BSA, platelets were lysed by STS and POL
concentrations above 0.02% (Fig. 3a and 3b). However,
increasing concentrations of BSA interfered with the lytic
activity of the sclerosants. At BSA concentrations above
4%, sclerosant concentrations greater than 0.2% were
required to lyse platelets. POL did not dissolve platelets
as completely as STS.
Effect of plasma on the release of
platelet-derived microparticles
We have previously shown that low concentrations of
sclerosants release PDMP.5 Here we investigated the poten-
tial inhibitory effects of plasma on the release of PDMP.
Microparticle formation was induced by STS or POL concen-
trations of 0.01% in washed platelet samples, whereas
higher concentrations (0.15%) were required to achieve
the same in PRP samples. This suggests that plasma confers
a degree of lytic protection to the platelets. Both agents at
higher concentrations (>0.2%) in saline reduced the PDMP
count (Fig. 4b).
Neutralisation of haemolytic effects of
sclerosants by procaine, lignocaine
and protamine
Results obtained are shown in Tables 2 and 3. It is apparent
that the haemolytic activity of STS which emerged at
a concentration of 0.25% was not impeded by 0.1% procaine
or lignocaine. Indeed these drugs slightly increased the
haemolytic activity of STS. The best neutralising agent for
STSwasBSAwhichat a lowconcentration of 0.5%, completely
blocked haemolysis at STS concentrations of up to 0.05%.
Protamine sulphate had a mild neutralising effect on STS.
As noted earlier, POL was more haemolytic at lower concen-
trations when compared with STS in saline. The haemolytic
activity of POL was inhibited only by BSA and not procaine,
lignocaine or protamine at the concentrations examined.
Figure 3 Turbidity studies performed to determine the ef-
fects of detergent sclerosants on washed platelets in the pres-
ence of varying concentrations of bovine serum albumin (BSA
4%,, 2% 6, 1% , 0.5% *, 0.25%B, 0.125 þ, 0% ). Baseline
zero STS or POL is shown as ‘‘0.001%’’ so as to be accommo-
dated on a logarithmic scale. (a) STS, (b) POL. Figure 4 Effect of plasma proteins on sclerosant induced
platele-derived microparticle (PDMP) formation. PDMP counts
in platelet rich plasma (C) and a washed platelet suspension
(B) incubated with varying concentrations of (a) STS and (b)
POL.
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Results obtained are shown in Fig. 5a and b. STS reduced
the amount of stainable material in the microwells in
a concentration-dependent manner. POL had less lytic
effects on endothelial cells (results not shown). Both
plasma and BSA reduced the lytic effects of STS on the
endothelial cells (Fig. 5a and b).
Discussion
It is well known that detergents including STS and POL
disrupt lipid and phospholipid membranes.1 Detergents are
widely used to permeabilise cells allowing the ingress of
various dyes and markers. For instance, sodium dodecyl
sulphate (SDS), an anionic detergent with a similar chemi-
cal structure to STS, readily dissolves most cells even atrelatively low concentrations.11 Fegan noted that red cell
lysis was caused by STS concentrations of 0.125% or greater
in normal saline added to heparinised blood.12
In this study, both detergent sclerosants were shown to
cause haemolysis, platelet lysis and endothelial cell lysis.
Both drugs released PDMP in low concentrations but
destroyed them at higher concentrations. Platelets
appeared to be more resistant to lysis by sclerosants
when compared with red blood cells (Table 1). This is
possibly due to the differences in the composition of the
cell membranes and the internal structure of these cells.
Previous studies have reported platelet rich clots occluding
femoral arterial eversion grafts to be much more resistant
to lysis than erythrocyte rich whole blood clots.13
Table 2 Haemolysis of washed red cells in saline by STS
and the effect of various therapeutic agent additives. No
haemolysis is indicated by ‘‘O’’, partial haemolysis by
‘‘þ’’, and complete haemolysis by ‘‘þþ’’. Haemolysis
defined as lysis of more than 50% of red blood cells
STS (%) No
additive
Lignocaine
0.1%
Procaine
0.1%
Protamine
0.01%
BSA
0.5%
0 O O O O O
0.010 O O O O O
0.020 O O O O O
0.025 O þþ þ O O
0.030 þ þþ þþ O O
0.040 þþ þþ þþ O O
0.050 þþ þþ þþ þ O
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nents appeared to neutralise the lytic effects of sclerosants
in an in vitro setting. STS was 50 fold and POL was 163 fold
less haemolytic in blood than in saline (Table 1). These
findings highlight the importance of plasma components
and in particular albumin in protecting against the lytic
effects of detergent sclerosants. It can be concluded that
lower concentrations of sclerosants can achieve the same
lytic effects if blood is removed from the target vessels.
In a clinical setting, this can be partially achieved by an
empty vein technique or if blood is displaced by foam,
diluted by an infusion of saline, or forced out by peri-
venous infiltration of saline or tumescent anaesthesia.
The displacement of blood from the vessel lumen
decreases the exposure of the sclerosant to plasma compo-
nents and increases the exposure of the endothelial lining
of the vessel lumen to the active agent. This concept
may partly explain why foam sclerosants are found to be
more effective when compared with the liquid
counterparts.
Compared with the 3 other drugs tested (procaine,
lignocaine and protamine), albumin proved to be the best
neutralising drug with the potential to completely block
sclerosant-dependent cell lysis. Albumin is a transport
protein with the potential to bind to a number of drugs
via two major and three minor binding sites.14 The binding
strength of a drug to serum albumin is the main factor thatTable 3 Haemolysis of washed red cells in saline by POL
and the effect of various therapeutic agent additives. No
haemolysis is indicated by ‘‘O’’, partial haemolysis by
‘‘þ’’ and complete haemolysis by ‘‘þþ’’
POL (%) No
additive
Lignocaine
0.1%
Procaine
0.1%
Protamine
0.01%
BSA
0.5%
0 O O O O O
0.008 O O O O O
0.015 þþ þþ þþ þþ O
0.02 þþ þþ þþ þþ O
0.03 þþ þþ þþ þþ O
0.035 þþ þþ þþ þþ O
0.05 þþ þþ þþ þþ þ
Figure 5 Effect of STS on cultured endothelial cells in the
presence of varying concentrations of (a) bovine serum albu-
min (BSA 1.5% C, 0.5% -, 0.17% :, 0% B) and (b) normal
plasma (NP/2 C, NP/6 -, NP/18 :, NP/54 B).
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available to reach the target tissue. STS has been shown
to bind to 10-11 sites on BSA with Kd (M) of 6.7 107.15
Apart from albumin, other plasma proteins and possibly
lipoproteins may also play a role in neutralisation of
detergent sclerosants. We have previously isolated
a precipitate induced by STS which was found to be mainly
apolipoprotein B and fibrin(ogen).5 STS can also form
complexes with other proteins such as gammaglobulin.16
Association of detergents with lipid-related proteins is
probably not unexpected and we have also noticed an insol-
uble STS-red cell complex form when washed red cells are
lysed by STS. It is also conceivable that POL is binding to
plasma components other than albumin. We observed POL
to be more active than STS in both saline and with 4% BSA
present (Table 1). 0.0035% POL was required to achieve
50% haemolysis in saline, whereas 0.1% (28.6) was
required in the presence of 4% BSA and 0.57% (163) was
required in whole blood (Table 1). These findings imply
that other plasma components play an important role in
neutralisation of POL. These plasma components and their
interaction with POL have not been characterised.
Sclerosants have been observed to enter the deep
venous system during sclerotherapy. It is likely that the
concentration of the active drug entering the deep veins is
quite low due to neutralisation and dilution effects.
However, we have previously demonstrated low concentra-
tions of sclerosants to possess procoagulant properties5 and
deep vein thrombosis has been described in association
with the clinical use of low concentration sclerosants.17
Therefore, infusion of large volumes of detergent sclero-
sants from a single access point should be avoided as an ini-
tial high concentration will undergo a neutralisation and
dilution process reaching the deep veins in a low concentra-
tion ‘pro-coagulant window’ which may lead to deep vein
thrombosis (DVT). The extent of the neutralisation process
depends on the volume of blood with which the sclerosant
is mixed at the time of injection. Larger blood volumes will
dilute and neutralise the sclerosants more significantly.
Based on our present findings, 1 ml of blood will contain
enough plasma protein to neutralise 0.2 ml of STS and
0.4 ml of POL at the therapeutic concentration of 3%. The
quantity of the intravascular blood volume depends on
the diameter of the target vessel and the length of the tar-
get segment. The sympathetic tone is responsible for the
vessel diameter at any time. Anxiety, pain, cold tempera-
ture, vasoactive medications and other factors can induce
vasoconstriction reducing the volume of the intravascular
blood in the target segment. Leg elevation can help with
emptying the vessel and reducing the intravascular blood.
Needle penetration can also induce vasospasm and further
reduce the vessel diameter. Furthermore, bubbles gener-
ated from foam sclerosants have been observed at distant
sites such as the right atrium.18,19 Sample collection from
the right atrium is an invasive procedure and to our knowl-
edge has not been attempted as yet. Given our present
findings however, these bubbles are highly unlikely to
have any sclerosing activity due to the neutralisation and
dilution process.
We compared the protective effects of three other
agents with albumin. Procaine is an anaesthetic agent
and its role in preventing STS induced tissue necrosis isnot well understood. Procaine has been presumed to bind
and inactivate STS.20,21 In this study, procaine and ligno-
caine slightly increased the haemolytic activity of STS
and showed no neutralising properties. Veno-arteriolar
axonal reflex has been previously proposed by one of the
authors to be one of the pathogenic mechanisms of post-
sclerotherapy ischemic ulcers.7 Procaine used as a local
anaesthetic possibly impedes this axonal reflex, thus exert-
ing a protective effect. The clinical utility of Procaine in
prevention of STS induced tissue necrosis requires further
evaluation.
In this study, Protamine was found to mildly neutralize
STS. A slight turbidity was apparent after this interaction.
This is possibly because the positively charged protamine
ionically binds to the negatively charged STS forming an
insoluble complex.22 Protamine is well known to neutralize
other negatively charged polymeric molecules such as
heparin.22,23 POL is an anionic agent and predictably,
Protamine did not inhibit the lytic effects of POL. None of
the other agents, except for BSA, inhibited the lytic effects
of POL.
In summary, both STS and POL at therapeutic concentra-
tions have lytic effects on red cells, platelets, and endothe-
lial cells and release procoagulant platelet-derived
microparticles. STS causes significant haemolysis at concen-
trations higher than 0.3% in whole blood. Serum albumin
neutralizes the lytic effects of both sclerosants. Lower
sclerosant concentrations are required to achieveequivalent
lytic effects in the absence of plasma components. Foam
sclerosants are more effective than liquids in sclerosing
blood vessels possibly due to displacement of blood and
a reduced exposure to serum albumin and other plasma
components. Neutralisation of sclerosants by albumin possi-
bly plays a role in the low incidence of post-sclerotherapy
deep vein thrombosis and low incidence of distal effects.
Finally, procaine and lignocaine have no protective effect on
the lytic properties of detergent sclerosantswhile protamine
confers a mild degree of protection.
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